These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 33599731)

  • 1. Erythrocytosis in a Large Cohort of Trans Men Using Testosterone: A Long-Term Follow-Up Study on Prevalence, Determinants, and Exposure Years.
    Madsen MC; van Dijk D; Wiepjes CM; Conemans EB; Thijs A; den Heijer M
    J Clin Endocrinol Metab; 2021 May; 106(6):1710-1717. PubMed ID: 33599731
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased risk of erythrocytosis in men with type 2 diabetes treated with combined sodium-glucose cotransporter-2 inhibitor and testosterone replacement therapy.
    Gosmanov AR; Gemoets DE; Schumacher KA
    J Endocrinol Invest; 2024 Oct; 47(10):2615-2621. PubMed ID: 38536657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: an analysis of 388 individuals diagnosed with gender dysphoria.
    Meyer G; Mayer M; Mondorf A; Flügel AK; Herrmann E; Bojunga J
    Eur J Endocrinol; 2020 Feb; 182(2):149-156. PubMed ID: 31751300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of testosterone formulations on hematocrit in transgender individuals: A systematic review.
    Okano SHP; Braga GC; Cantelli DAL; Filho LASP; Brito LGO; Lara LADS
    Andrology; 2024 Jul; ():. PubMed ID: 39011565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone and other treatments for transgender males and non-binary trans masculine individuals.
    Dimakopoulou A; Seal LJ
    Best Pract Res Clin Endocrinol Metab; 2024 Sep; 38(5):101908. PubMed ID: 38997938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective evaluation of hematocrit in gender-affirming hormone treatment: results from European Network for the Investigation of Gender Incongruence.
    Defreyne J; Vantomme B; Van Caenegem E; Wierckx K; De Blok CJM; Klaver M; Nota NM; Van Dijk D; Wiepjes CM; Den Heijer M; T'Sjoen G
    Andrology; 2018 May; 6(3):446-454. PubMed ID: 29602229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Toward a Lowest Effective Dose of Cyproterone Acetate in Trans Women: Results From the ENIGI Study.
    Kuijpers SME; Wiepjes CM; Conemans EB; Fisher AD; T'Sjoen G; den Heijer M
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e3936-e3945. PubMed ID: 34125226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erythrocytosis Is Rare With Exogenous Testosterone in Gender-Affirming Hormone Therapy.
    Krishnamurthy N; Slack DJ; Kyweluk M; Cullen O; Kirkley J; Safer JD
    J Clin Endocrinol Metab; 2024 Apr; 109(5):1285-1290. PubMed ID: 38011684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence.
    Wierckx K; Van Caenegem E; Schreiner T; Haraldsen I; Fisher AD; Toye K; Kaufman JM; T'Sjoen G
    J Sex Med; 2014 Aug; 11(8):1999-2011. PubMed ID: 24828032
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombotic risk associated with gender-affirming hormone therapy.
    Mullins TLK; Mullins ES
    J Thromb Haemost; 2024 Aug; 22(8):2129-2139. PubMed ID: 38795871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erythrocytosis in Gender-Affirming Care With Testosterone.
    Porat AT; Ellwood M; Rodina M; Dianat S
    Ann Fam Med; 2023; 21(5):403-407. PubMed ID: 37748907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Short- and long-term clinical skin effects of testosterone treatment in trans men.
    Wierckx K; Van de Peer F; Verhaeghe E; Dedecker D; Van Caenegem E; Toye K; Kaufman JM; T'Sjoen G
    J Sex Med; 2014 Jan; 11(1):222-9. PubMed ID: 24344810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of erythrocytosis in transgender individuals undergoing testosterone therapy: a systematic review.
    Scala A; Graziani A; Vianello F; Ferlin A; Garolla A;
    Minerva Endocrinol (Torino); 2024 Jun; 49(2):205-216. PubMed ID: 39028210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elevated Dihydrotestosterone is Associated with Testosterone Induced Erythrocytosis.
    Aghazadeh M; Pastuszak AW; Johnson WG; McIntyre MG; Hsieh TM; Lipshultz LI
    J Urol; 2015 Jul; 194(1):160-5. PubMed ID: 25596360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender-affirming hormone treatment: friend or foe? Long-term follow-up of 755 transgender people.
    Santi D; Spaggiari G; Marinelli L; Cacciani M; Scipio S; Bichiri A; Profeta A; Granata ARM; Simoni M; Lanfranco F; Manieri C; Ghigo E; Motta G
    J Endocrinol Invest; 2024 May; 47(5):1091-1100. PubMed ID: 37889433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Obstructive Sleep Apnea Is Associated With Polycythemia in Hypogonadal Men on Testosterone Replacement Therapy.
    Lundy SD; Parekh NV; Shoskes DA
    J Sex Med; 2020 Jul; 17(7):1297-1303. PubMed ID: 32307242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of gender affirming hormone treatment in transgender individuals - a retrospective cohort study.
    Muir CA; Guttman-Jones M; Man EJ
    Endocrine; 2024 Jul; 85(1):370-379. PubMed ID: 38386168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trough serum testosterone predicts the development of polycythemia in hypogonadal men treated for up to 21 years with subcutaneous testosterone pellets.
    Ip FF; di Pierro I; Brown R; Cunningham I; Handelsman DJ; Liu PY
    Eur J Endocrinol; 2010 Feb; 162(2):385-90. PubMed ID: 19903801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Erythrocytosis Following Testosterone Therapy.
    Ohlander SJ; Varghese B; Pastuszak AW
    Sex Med Rev; 2018 Jan; 6(1):77-85. PubMed ID: 28526632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Letter to the Editor From Laidlaw et al: "Erythrocytosis in a Large Cohort of Transgender Men Using Testosterone: A Long-term Follow-up Study on Prevalence, Determinants, and Exposure Years".
    Laidlaw MK; Van Mol A; Van Meter Q; Hansen JE
    J Clin Endocrinol Metab; 2021 Nov; 106(12):e5275-e5276. PubMed ID: 34297088
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.